XML 63 R30.htm IDEA: XBRL DOCUMENT v3.20.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Dec. 31, 2019
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  
Schedule of estimated useful lives of property, plant and equipment

 

 

 

 

Production equipment

    

3 to 13 years

Office furniture and equipment

 

3 to 10 years

Buildings

 

39 years

Building improvements

 

15 years

 

Schedule of significant customers

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Years Ended December 31,

 

 

    

2019

    

2018

    

2017

 

Number of significant customers

 

 

 3

 

 

 2

 

 

2

 

Aggregate dollar amount of net sales to significant customers

 

$

19.0 million

 

$

13.1 million

 

$

14.0  million

 

Percentage of net sales to significant customers

 

 

45.6

%

 

39.2

%

 

40.5

%

 

Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the year ended December 31, 2019:

 

    

 

 

    

Blood 

    

 

 

    

 

 

    

 

 

 

 

 

 

 

Collection 

 

EasyPoint(R) 

 

Other 

 

Total Product

Geographic Segment

 

Syringes

 

Products

 

Needles

 

Products

 

 Sales

U.S. sales

 

$

26,722,414

 

$

2,130,767

 

$

2,970,374

 

$

74,369

 

$

31,897,924

North and South America sales (excluding U.S.)

 

 

7,863,796

 

 

6,313

 

 

7,996

 

 

370,885

 

 

8,248,990

Other international sales

 

 

1,052,217

 

 

578,617

 

 

635

 

 

18,796

 

 

1,650,265

Total

 

$

35,638,427

 

$

2,715,697

 

$

2,979,005

 

$

464,050

 

$

41,797,179

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the year ended December 31, 2018:

 

    

 

 

    

Blood 

    

 

 

    

 

 

    

 

 

 

 

 

 

 

Collection

 

EasyPoint(R) 

 

Other 

 

Total Product 

Geographic Segment

 

Syringes

 

 Products

 

Needles

 

Products

 

Sales

U.S. sales

 

$

23,803,483

 

$

1,365,936

 

$

3,401,389

 

$

75,766

 

$

28,646,574

North and South America sales (excluding U.S.)

 

 

3,521,823

 

 

8,805

 

 

252

 

 

66,564

 

 

3,597,444

Other international sales

 

 

940,740

 

 

48,101

 

 

11,768

 

 

30,075

 

 

1,030,684

Total

 

$

28,266,046

 

$

1,422,842

 

$

3,413,409

 

$

172,405

 

$

33,274,702

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the year ended December 31, 2017:

 

    

 

 

    

Blood 

    

 

 

    

 

 

    

 

 

 

 

 

 

 

Collection 

 

EasyPoint(R) 

 

Other 

 

Total Product 

Geographic Segment

 

Syringes

 

Products

 

Needles

 

Products

 

Sales

U.S. sales

 

$

23,794,258

 

$

1,098,667

 

$

2,065,777

 

$

57,010

 

$

27,015,712

North and South America sales (excluding U.S.)

 

 

6,182,952

 

 

3,859

 

 

 —

 

 

193,934

 

 

6,380,745

Other international sales

 

 

1,032,508

 

 

43,473

 

 

 —

 

 

21,400

 

 

1,097,381

Total

 

$

31,009,718

 

$

1,145,999

 

$

2,065,777

 

$

272,344

 

$

34,493,838

 

Schedule of earnings per share

 

 

 

 

 

 

 

 

 

 

 

 

 

Years Ended December 31,

 

    

2019

    

2018

    

2017

Net income (loss)

 

$

3,148,234

 

$

(1,339,943)

 

$

(3,736,038)

Preferred dividend requirements

 

 

(702,618)

 

 

(704,996)

 

 

(704,996)

Income (loss) applicable to common shareholders

 

$

2,445,616

 

$

(2,044,939)

 

$

(4,441,034)

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

 

32,672,475

 

 

32,666,454

 

 

31,958,121

Weighted average common and common equivalent shares outstanding - assuming dilution

 

 

32,672,475

 

 

32,666,454

 

 

31,958,121

Basic earnings (loss) per share

 

$

0.07

 

$

(0.06)

 

$

(0.14)

Diluted earnings (loss) per share

 

$

0.07

 

$

(0.06)

 

$

(0.14)

 

Schedule of share-based compensation costs

 

 

 

 

 

 

 

 

 

 

 

 

 

Years Ended December 31,

 

    

2019

    

2018

    

2017

Cost of sales

 

$

 —

 

$

 —

 

$

272,811

Sales and marketing

 

 

 —

 

 

 —

 

 

143,255

Research and development

 

 

 —

 

 

 —

 

 

45,174

General and administrative

 

 

 —

 

 

 —

 

 

210,983

 

 

$

 —

 

$

 —

 

$

672,223

 

Schedule of ASU 2016-02 lease adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance Sheet as of December 31, 2018

 

 As Previously     Reported

    

New Lease Adjustment

    

 

    

As Restated

Other assets

 

$

2,849

 

$

163,007

 

 

 

 

$

165,856

Other current liabilities

 

$

1,387,287

 

$

80,648

 

 

 

 

$

1,467,935

Other long term-liabilities

 

$

-

 

$

82,359

 

 

 

 

$

82,359